Seeking Alpha

Leerink, others defend Amarin after generic Lovaza fears trigger rout

  • Somebody, somewhere sure is selling shares of Amarin (AMRN -7.1%) following a U.S. district court's ruling on generic Lovaza, but it sure is difficult to discern any negativity in the market chatter.
  • Leerink's Joseph Schwartz says generic Lovaza might not compete with Vascepa on price as much as on efficacy and safety.
  • There's also talk that Citi and Jefferies are out defending the shares, with Citi calling a buying opportunity.
  • Additionally, there are even some notable bears that seem to think the sell-off is overdone.
Comments (3)
  • rrobster
    , contributor
    Comments (144) | Send Message
    Regarding Lovaza and Vascepa: two different profiles entirely. People need to do their homework. This is an unfounded sell-off with no solid causation. It does present a great entry point!
    12 Sep 2013, 02:23 PM Reply Like
  • willbensam
    , contributor
    Comments (7) | Send Message
    Buy, Buy, Buy!!!
    12 Sep 2013, 02:35 PM Reply Like
  • mitrado
    , contributor
    Comments (2015) | Send Message
    Who cares!? Let's have another sell-off, please. The cheaper, the better!
    13 Sep 2013, 12:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs